Celera's Q4 Revenues Increase 15 Percent; Swings to Loss | GenomeWeb

NEW YORK (GenomeWeb News) – Celera reported after the close of the market on Tuesday that its fourth-quarter revenues rose 15 percent year over year, while the firm swung from a profit to a loss on increased SG&A spending.

The Alameda, Calif.-based personalized disease management products firm brought in revenues of $47.3 million for the three-month period ended Dec. 27, compared to revenue of $40.3 million for the three-month period ended Dec. 31, 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.